A Vision for the New Year of Medicine People

Lei Wang is executive vice president of AstraZeneca Worldwide

I hope that Chinese-style innovation can go global

This year is the 7th year that Wang Lei has taken the helm of AstraZeneca China, and he has no medical background and no overseas education, and he has already proved his strength with his performance, and this local professional manager has built AstraZeneca into the most "localized" multinational pharmaceutical company with the most policy dividends.

Speaking about the Vision for the New Year, Wang Lei, Global Executive Vice President of AstraZeneca, hopes that Chinese-style innovation can go abroad, go to the world, and lead the world. Truly do Innovative R&D in China.

"New lung cancer drugs are listed, a large number of new drugs have entered medical insurance, rare disease divisions have been established in China, industrial funds have begun to invest, dizhe pharmaceutical (688192. SH) Sci-Tech Board listing..." Wang Lei told the Health Times reporter that in the field of tumors, AstraZeneca has truly achieved price for volume and benefited more patients.

The landing of the Global R&D China Center in Shanghai is a milestone event for AstraZeneca in China in 2021, which means it will accelerate the incubation of more innovative drugs and solutions in China. Wang Lei introduced that the Global R&D China Center can realize the simultaneous research and development of new drugs around the world, further solve China's unmet medical needs, and is committed to accelerating the development of local innovative drugs and benefiting the world.

Wu Xiaobin is president and chief operating officer of BeiGene

Walk with patients and fight diseases

Not long ago, BeiGene landed on the Science and Technology Innovation Board, realizing the listing of "US stocks + Hong Kong stocks + A shares". Wu Xiaobin has joined BeiGene for 3 years, witnessing it step by step becoming an innovative pharmaceutical company with strong R&D capabilities, many changes in the status quo of the therapeutic field and filling the gaps in clinical treatment.

"2021 started with uncertainty, and it's reassuring that we've turned a lot of uncertainty into certainty." Wu Xiaobin introduced that in 2021, three drugs and new indications independently developed by BeiGene will be included in the medical insurance directory. Among them, the PD-1 drug tirelizumab injection added three new indications, the BTK inhibitor zebutinib capsule added an indication, and the PARP inhibitor Pamipali capsule entered medical insurance for the first time.

As an innovative pharmaceutical company with local origins, BeiGene has been approved for commercialization in more than 40 countries and regions around the world. Wu Xiaobin said: "Walking with patients and fighting diseases is the mission of every medical person and our eternal vision. ”

Min Liu is the Chief Commercial Officer of Cinda Biologics

In the next 2 to 3 years, it is expected to launch more than 10 innovative drugs

This year marks the 10th anniversary of the establishment of Cinda Biologics and the golden decade in the history of China's innovative drug development. In the view of Liu Min, chief commercial officer of Cinda Biologics, "2021 is a very meaningful year. ”

In 2011, Innovent Biologics started from scratch and broke the "double ten law" of innovative drug research and development, and in the past ten years, the achievements have been remarkable, and 4 large molecule biological drugs and 2 small molecule drugs have been approved for marketing. As a Chinese innovative pharmaceutical enterprise, Innovent Biologics has now laid out 26 clinical stage products, covering both oncology and non-tumor areas.

From R&D to commercialization, Innovent Biologics ushered in a harvest period. Liu Min introduced, "This year's sales performance is remarkable, with sales of 2.2 billion yuan in the first three quarters. As an innovative drug enterprise, how to open up the "last mile" of innovative drug landing is also a challenge for Cinda Biologics. Liu Min believes that the policy trend is good in 2021, but there is still a lot of work to continue to advance, and in 2022, Cinda Bio will further promote domestic innovative drugs and benefit more patients.

Yao Zhao is a Director of Omron Healthcare (China).

Hope to provide better cardiovascular and cerebrovascular testing

In 1993, Omron Healthcare set up a production base in China. Today, it has grown to become the leading medical device company in the sphygmomanometer industry. By 2021, Omron sphygmomanometers have sold more than 300 million units worldwide and are widely used in 110 countries around the world.

As the first Chinese director of Omron Healthcare Group in the world, Zhao Yao has been deeply involved in the medical device industry for 25 years, and under his leadership, Omron China's sales in the group account for 27% of the world's total, and the growth rate continues to remain the world's first.

"This year has been a fruitful year for Omron, not only with new strategic directions and operational results in chronic disease management projects, but also by actively expanding cross-border cooperation opportunities." Zhao Yao introduced that we are ready to launch new ventilators and oxygen concentrator products next year, hoping to play a role in the prevention and control of the epidemic.

In addition, the upgrading of electronic blood pressure monitors and blood glucose meters is also the key planning of enterprises next year.

Zhao Lijian is the CEO of BGI

"Gene technology for the benefit of mankind" began a new journey

In the past two years, wherever a local epidemic has occurred, there is a "FireEye" laboratory and BGI Gene. In January 2021, the "FireEye" laboratory was built in Hebei in only 10 hours, put into use in 21 hours, and can test more than 1 million samples per day. In June, the world's largest air film "Fire Eye" was unveiled in Panyu, Guangzhou, with a maximum daily detectable sample of 2.1 million copies.

Zhao Lijian, CEO of BGI, introduced that since joining the Human Genome Project, BGI has achieved leapfrog development in the past 22 years and laid the foundation for genome science. Therefore, in the epidemic situation, BGI can output the integrated integrated solution of the "FireEye" laboratory, which is the application of the core technology independent mastery. "In the future, BGI will further take the channel of 'FireEye' laboratory construction as the starting point, continuously strengthen overseas business and global expansion, and work with local medical institutions and public health systems to explore its application in the fields of tumor prevention and control, surveillance of infectious diseases and other fields."

Xiang Li is the CEO of Kayudi Biotech

Scientific and technological innovation to achieve rapid detection of nucleic acids

From 100 yuan to tens of yuan, the price of nucleic acid testing continues to decrease, as a leader in the field of nucleic acid testing industry, Kayudi Bio witnesses all this.

Li Xiang, founder/CEO of Kayudid Biology, introduced that the epidemic in a city with a population of more than 5 million needs to be tested for nucleic acid within 2 days. Fast, instant detection is already a need, which requires continuous technological innovation and upgrading.

In 2020, Li Xiang and his team undertook the task of major national special projects and the State Council's testing special class, broke through the nucleic acid rapid detection technology for the new crown virus in China, and the self-developed flash test Flash20 platform realized the technical innovation from sample to result in 30 minutes, and the sensitivity reached 400 copies/ml.

In order to avoid false positives for cross-contamination between samples and infection by inspectors, Kayudy has developed a fully automated nucleic acid testing workstation that can be closed without opening the lid and tested in just 15 minutes.

Dong Lijun is the executive vice president of Luoxin Pharmaceutical

More drugs specific to children have emerged

"Grasp the development trend of the industry and follow the trend." In the view of Dong Lijun, executive vice president and chief operating officer of Luoxin Pharmaceutical, this is a strategy to ensure the long-term development of an enterprise.

In December 2021, the National Health Commission publicly solicited opinions on the Measures for the Administration of the National Essential Drugs List (Revised Draft), and for the first time proposed the children's drug list. The state released a positive signal for the children's drug market, and In August 2021, Luoxin Pharmaceutical was approved to list China's first ambroxol hydrochloride spray, which is the first and only children's exclusive expectorant spray in China to fill the gap in the children's drug market. In addition to the drug, the marketing application of 1 class 1 new drug of Rosin Pharmaceutical for Tigorasheng tablets was accepted, and 5 inhalation preparations ANDA were approved by the US Food and Drug Administration, marking the harvest period of Luoxin Pharmaceutical's innovation-driven transformation.

She said that she hopes that the medical insurance policy in the new year can allow class I and ii innovative drugs to enter medical insurance faster at the right price and help patients afford innovative drugs.

Liang Guo, CEO of Clover Bio

It is expected that the new crown vaccine candidate will be available as soon as possible

On November 5, 2021, Clover began listing on the main board of the Hong Kong Stock Exchange.

Clover's workforce has multiplied in the past year, with more than 800 people worldwide in 18 countries.

"It is these first-class talents from all over the world who have made our 2021 stand out." Introduction of Chief Executive Officer and Executive Director Liang Guo.

In collaboration with a strong team, Clover announced in September that the COVID-19 vaccine candidate SCB-2019 is 100% effective against severe and hospitalized COVID-19 from any strain, and 84% against moderate to severe COVID-19 from any strain, with good safety.

Liang Guo said with confidence, "In the new year, I eagerly look forward to the day when the SCB-2019 COVID-19 vaccine candidate will be launched, and fulfill our commitment to support vaccine fairness and help people in need around the world." ”

Jiang Haochuan is the president of Mingfeng Medical and the president of the research institute

Break the technical bottleneck of innovative medical devices

In the two years since the outbreak of the epidemic, in order to prevent and control the epidemic, many companies have joined the research and development of epidemic products, and Mingfeng Medical is one of them.

Mingfeng Medical Cabin/Vehicle CT is an anti-epidemic weapon, the first time to help Wuhan, Lu'an, Nanjing, Zhengzhou, Zhangjiajie, Xiamen and other parts of the country to fight the epidemic, and in December 2021, Mingfeng Medical Cabin / Vehicle CT is still in the front line of the fight against the epidemic in Hangzhou.

In 2021, Mingfeng Medical's QuantumEye799 obtained a medical device registration qualification certificate. Jiang Haochuan, president of Mingfeng Medical, introduced, "This means that products can be put on the market next year, and this is also an important market plan for enterprises in the new year." ”

"I hope that in the new year, the epidemic can pass sooner." Jiang Haochuan said that in the new year, it is also hoped that the state can increase innovation efforts, as a medical device enterprise, it can also seize the opportunity to do more independent innovation products and break the technical bottleneck of the card neck.

Xu Songshan, founder and chairman of Northland

It is expected that the review and approval of new drugs will be accelerated

On November 15, 2021, the Beijing Stock Exchange opened, as the first up-and-down stock after the opening of the Beijing Stock Exchange, the bio-innovative pharmaceutical company Northland was favored by the capital market. Xu Songshan, chairman of Northland, said, "In 2021, the biggest gain of our company is that it has been listed on the Beijing Stock Exchange and has become a real A-share pharmaceutical company. ”

Founded in 2004, Northland is an innovative biopharmaceutical company focusing on the research and development and production of gene therapy drugs, recombinant protein drugs and ophthalmic drugs, and its bio-innovative drugs are still in the product development stage for 17 years.

In the new year, Xu Songshan's biggest wish is that the new drugs developed can be listed as soon as possible.

He introduced, "Next year, we will continue to advance clinical research on new drugs as planned. At the same time, the construction of biological engineering drug production base. In this way, after the new drug is approved, the drug can be produced and sold in the shortest possible time. ”